Press

FILAMENT HEALTH TO HOST VIRTUAL INVESTOR UPDATE

May 8 • 2 min read

Filament Health Corp. (OTCQB: FLHLF / NEO: FH / FSE: 7QS), a clinical-stage natural psychedelic drug development company, today announced that it will host a virtual update for investors and shareholders on Thursday, May 18, 2023 at 2:00 p.m. Eastern (11:00 a.m. Pacific). During the event, Chief Executive Officer (CEO) Benjamin Lightburn and Chief Science Officer (CSO) Ryan Moss will discuss Filament’s recent progress including…

Clearmind Medicine Strengthens Scientific Advisory Board with Appointment of Prof. Joseph Tam

May 8 • 2 min read

Clearmind Medicine Inc. (NASDAQ: CMND / CSE: CMND / FSE: CWY), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, has appointed Professor Joseph (Yossi) Tam, D.M.D., Ph.D., to its Scientific Advisory Board (“SAB”). Prof. Tam is the Head of the Obesity and Metabolism Laboratory and…

MIND CURE AND LNG ENERGY GROUP ENTER INTO ARRANGEMENT AGREEMENT WITH RESPECT TO PREVIOUSLY ANNOUNCED BUSINESS COMBINATION TRANSACTION

May 8 • 26 min read

Mind Cure Health Inc. (CSE: MCUR / OTCQB: MCURF / FRA: 6MH) (“Mind Cure“, the “Company” or the “Resulting Issuer” following the completion of the Proposed Transaction (as defined below)) and LNG Energy Group Inc. (“LNG Energy“) are pleased to provide an update on the previously announced binding letter of intent dated November 17, 2022. Effective…

Algernon Pharmaceuticals Announces Closing of Rights Offering

May 8 • 3 min read

Algernon Pharmaceuticals Inc. (CSE: AGN / FRANKFURT: AGW0 / OTCQB: AGNPF) a Canadian clinical stage pharmaceutical development company announces that it has closed its previously announced rights offering which expired on April 27, 2023 (the “Rights Offering”). At closing, the Company issued 4,753,369 units (the “Units”) at the subscription price of $0.25 per Unit for total…

First Patient Dosed in Beckley Psytech’s Phase IIa Study of BPL-003 for Treatment Resistant Depression

May 5 • 3 min read

Beckley Psytech Ltd, a private, clinical-stage biotechnology company dedicated to addressing neuropsychiatric disorders by transforming psychedelics into effective and licensed medicines, announced today that the first patient has been dosed in its Phase IIa study evaluating BPL-003 as a potential therapy for Treatment Resistant Depression (TRD). BPL-003 is Beckley Psytech’s novel synthetic formulation of the…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441